The immunoproteome and multimorbidity: A Mendelian randomization study
Science Advances · 22.05.2026 · 12 (21)
DOI: 10.1126/sciadv.adz7117 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 22.05.2026. Verfasst von Nikita Hukerikar und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health Informatics, Faculty of Population Health Sciences, University College London, 222 Euston Road, London NW1 2DA, UK. Hauptthemen laut MEDLINE: Mendelian Randomization Analysis, Proteome, Multimorbidity. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institutes of Health, UK Research and Innovation, British Heart Foundation.
Abstract (Originalsprache)
Multimorbidity presents challenges for research and health care. We investigated how immune-proteins influence multiple diseases to identify shared mechanisms and therapeutic opportunities. Using eight large plasma proteome GWAS, we identified cis-acting variants for 151 immune-proteins and applied cis-Mendelian randomization to assess associations with 64 diseases and biomarkers. Protein-disease communities were derived using a knowledge graph integrating multiplicity-corrected associations, druggability, indications, and tissue-trait associations. Replication was sought in independent pQTLs, with colocalization applied to replicated signals. Immune-proteins were frequently implicated in coronary heart disease, venous thromboembolism, atrial fibrillation, type 2 diabetes, and Parkinson’s disease. Seven protein communities mapped to pathways including ficolin binding and antimicrobial peptides, enriched for proteins influencing multiple diseases. Several associations replicated with colocalization support, including APOE, CD163, and IL-6R across neurodegenerative, cardiometabolic, and inflammatory traits. We found strong genetic support for druggable immune-proteins with pleiotropic effects across common diseases, highlighting opportunities for indication expansion and therapeutic development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Health Informatics, Faculty of Population Health Sciences, University College London, 222 Euston Road, London NW1 2DA, UK.
- Institute of Cardiovascular Science, Faculty of Population Health, University College London, 69-75 Chenies Mews, London WC1E 6HX, UK.
- UCL British Heart Foundation Centre of Excellence, 69-75 Chenies Mews, London WC1E 6HX, UK.
- Department of Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam UMC, locatie AMC Postbus 22660, 1100 DD Amsterdam-Zuidoost, Netherlands.
- Department of Internal Medicine, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam UMC, locatie AMC Postbus 22660, 1100 DD Amsterdam-Zuidoost, Netherlands.
- Department of Internal Medicine, Tergooi MC, Laan van Tergooi 2, 1212 VG Hilversum, Netherlands.
ORCID-Profile: Nikita Hukerikar, Aroon D Hingorani, Arjen J Cupido, Folkert W Asselbergs, Chris Finan
Förderung
- National Institutes of Health
- UK Research and Innovation
- British Heart Foundation
- Rosetrees Trust
- UKRI/NIHR Multimorbidity Fund Mechanism and Therapeutics Research Collaborative
- UCL NIHR Biomedical Research Centre
Zitieren
APA
Hukerikar, N., Hingorani, A. D., Chopade, S., Cupido, A. J., Asselbergs, F. W., Finan, C., & Schmidt, A. F. (2026). The immunoproteome and multimorbidity: A Mendelian randomization study. Science Advances, 12(21). https://doi.org/10.1126/sciadv.adz7117
Vancouver
Hukerikar N, Hingorani AD, Chopade S, Cupido AJ, Asselbergs FW, Finan C, et al. The immunoproteome and multimorbidity: A Mendelian randomization study. Science Advances. 2026;12(21). doi:10.1126/sciadv.adz7117
BibTeX
@article{Hukerikar2026,
author = {Hukerikar, Nikita and Hingorani, Aroon D and Chopade, Sandesh and Cupido, Arjen J and Asselbergs, Folkert W and Finan, Chris and Schmidt, A Floriaan},
title = {The immunoproteome and multimorbidity: A Mendelian randomization study},
journal = {Science Advances},
year = {2026},
volume = {12},
number = {21},
doi = {10.1126/sciadv.adz7117}
}
EUVIMED